Recent Comments

Comment RSS

Abdominal Pain News and Research RSS Feed - Abdominal Pain News and Research

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Tips for staying safe and healthy during Thanksgiving holiday

19. November 2009 00:03
Visiting is a big part of the Thanksgiving holiday. But one place you don't want to stop by is the Emergency Department. [More]

Posted in: Healthcare News

Tags: , , ,

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

18. November 2009 10:31
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. [More]

Shire publishes new study results on INTUNIV Extended-Release Tablets

17. November 2009 04:21
Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone. [More]

Genentech submits sBLAs to the FDA for Avastin

17. November 2009 03:36
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy. [More]

FDA approves Lysteda for treating menorrhagia

16. November 2009 09:04
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , ,

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

16. November 2009 05:57
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. [More]

Lysteda tablets to treat menorrhagia approved by FDA

16. November 2009 00:07
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot. [More]

PillCam capsule endoscopy is useful and safe in children under eight years old: Study

13. November 2009 10:51
Given Imaging Ltd. today announced that a multi-center study published in the November edition of Gut showed PillCam capsule endoscopy of the small bowel to be just as useful and equally as safe in children under eight years old as it is in older children or adults. The prospective multicenter analysis was led by Annette Fritscher-Ravens M.D., Department of Interdisciplinary Endoscopy, University Hospital Kiel, Germany. [More]

Posted in: Child Health News | Device / Technology News

Tags: , , , , ,

Shire announces findings from Phase 3 study data with Vyvanse

13. November 2009 04:41
Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. [More]

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

13. November 2009 01:18
Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). [More]

Adolor commences clinical testing of its oral mu opioid receptor antagonist

13. November 2009 00:42
Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , ,

Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference

12. November 2009 06:35
Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers. [More]

Posted in: Drug Trial News | Disease/Infection News

Tags: , , , , ,

Data supports the use of ExAblate as a safe, effective and durable treatment for uterine fibroids

12. November 2009 03:13
InSightec Ltd. today announced that three new papers published in the November issue of Ultrasound in Obstetrics and Gynecology add to the growing body of data supporting the use of ExAblate(R) as a safe, effective and durable treatment for uterine fibroids. [More]

Posted in: Women's Health News

Tags: , , , , , ,

Prolonged ED wait time is associated with poor clinical outcomes

10. November 2009 04:27
One in four emergency department patients in 2006 waited longer to be evaluated by a clinician than recommended at triage, an increase from one in five in 1997, according to a report in the November 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. [More]

Posted in: Healthcare News

Tags: , , ,

Shire's INTUNIV for treating ADHD now available in the U.S.

9. November 2009 10:26
Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.